Search Results - therapeutics+%3e+cns+and+neurology

105 Results

Sort By:

Directed Differentiation Protocols to Derive Bone Fide Spinal Sensory Interneurons (UCLA Case No. 2022-224)

UCLA researchers from the Department of Neurobiology have developed innovative protocols to differentiate and expand spinal sensory interneurons for drug discovery and to utilize in cell replacement therapies to restore injured spinal cords. BACKGROUND: Spinal cord injuries (SCIs) can result in the loss of controlled movement and somatosensation, the...

Published: 10/10/2025 | Inventor(s): Samantha Butler

Keywords(s):

Category(s): Life Science Research Tools > Research Methods, Therapeutics > Stem Cells And Regenerative Medicine, Therapeutics > CNS and Neurology

Broad-Band Frequency Repetitive Transcranial Magnetic Stimulation for the Treatment of Neuropsychiatric Disorders (Case No. 2025-99J)

Summary: Researchers in UCLA's Semel Institute and Department of Psychiatry have developed an innovative approach to treating depression by optimizing repetitive Transcranial Magnetic Stimulation (rTMS), improving its effectiveness for the treatment of Major Depressive Disorder (MDD) and possibly diseases of the mind and brain. Background: Depression...

Published: 10/9/2025 | Inventor(s): Andrew Leuchter, Juliana Corlier, Thomas Valles

Keywords(s): Bioelectromagnetics, Brain, Deep Brain Stimulation, Electrical Brain Stimulation, energy-efficient, frequency modulation, Magnetic Field, Medical Device, medication efficacy, neural information, neural network, neural networks, neural signals, neural stimulation, neurobehavioral impairment, Neurocognitive, neurological disorders, Neuromodulation, Neuron, neurons, neuroscience, Neurostimulation, pulsed load modulation, therapy, treatment efficacy

Category(s): Medical Devices, Medical Devices > Neural Stimulation, Life Science Research Tools, Therapeutics > CNS and Neurology, Therapeutics

Antiviral Compounds Inhibiting Zika Virus (ZIKV), and Methods and Zika Treatment Thereof (UCLA Case No. 2025-241)

UCLA researchers from the Molecular and Medical Pharmacology Department and CNSI have identified antiviral compounds that effectively inhibit Zika virus infection and cytopathic effects, potentially leading to improved therapeutics and treatment outcomes. BACKGROUND: Zika virus (ZIKV), a flavivirus now endemic to several regions globally, can cause...

Published: 10/3/2025 | Inventor(s): Vaithilingaraja Arumugaswami, Robert Damoiseaux

Keywords(s):

Category(s): Life Science Research Tools > Screening Libraries, Diagnostic Markers > Immunology, Diagnostic Markers > Targets And Assays, Therapeutics > Infectious Diseases, Therapeutics > CNS and Neurology, Therapeutics > Immunology And Immunotherapy, Platforms > Diagnostic Platform Technologies

TRP: Human Schwannoma Cell Line (UCLA Case No. 2015-213)

UCLA researchers from the Department of Head & Neck Surgery have developed the only available human NF2 schwannoma cell line, offering an in vitro model for studying tumor cell biology and therapeutic development. BACKGROUND: Neurofibromatosis type 2 (NF2) is a rare autosomal dominant disorder caused by inactivating mutations in the NF2 tumor suppressor...

Published: 10/1/2025 | Inventor(s): Marco Giovannini

Keywords(s):

Category(s): Life Science Research Tools > Cell Lines, Therapeutics > Oncology, Therapeutics > CNS and Neurology

TRP: Cell Lines Expressing a DNA Construct Expressing Mutant TRPV4 (UCLA Case No. 2021-361)

UCLA researchers from the Department of Molecular, Cell, and Developmental Biology have developed stable cell lines expressing wild-type or disease-associated mutant TRPV4 channels, providing a powerful platform for mechanistic and drug discovery studies. BACKGROUND: TRPV4 is a non-selective cation channel that regulates calcium influx in response...

Published: 10/1/2025 | Inventor(s): Daniel Cohn

Keywords(s):

Category(s): Life Science Research Tools > Cell Lines, Therapeutics > Musculoskeletal Disease, Therapeutics > CNS and Neurology

Therapeutic Targets from Subproteomes of Astrocytes and Neurons (UCLA Case No. 2024-162)

Contact UCLA Technology Development Group to learn more.

Published: 9/29/2025 | Inventor(s): Baljit Khakh

Keywords(s):

Category(s): Therapeutics > CNS and Neurology

Molecular Regulation of Stroke-Resistant Neurons (UCLA Case No. 2020-937)

Researchers in the Department of Neurology at UCLA have identified pharmacologic compounds capable of crossing the blood brain barrier that dramatically promote neurite outgrowth after stroke, thereby promoting recovery. Background: A stroke occurs when the blood supply of oxygen is interrupted to the brain, preventing brain tissue from receiving oxygen...

Published: 10/8/2025 | Inventor(s): Jason Hinman

Keywords(s):

Category(s): Therapeutics > CNS and Neurology

Compounds that Disaggregate Alzheimer's Disease-Associated Fibrils of Tau Protein (UCLA Case No. 2022-145, 2025-329)

Contact UCLA Technology Development Group to learn more.

Published: 9/19/2025 | Inventor(s): David Eisenberg

Keywords(s):

Category(s): Therapeutics > CNS and Neurology

Small molecule sAPPalpha enhancers that inhibit brain p-Tau as a therapeutic for Alzheimer’s Disease (UCLA Case No. 2025-163)

Contact UCLA Technology Development Group to learn more.

Published: 9/18/2025 | Inventor(s): Varghese John, Dongwook Wi, Jesus Campagna

Keywords(s):

Category(s): Therapeutics > CNS and Neurology

A Duplex Electrochemiluminescence Immunoassay for Total α-Synuclein and PS129-α-Synuclein (UCLA Case No. 2024-132)

Synucleinopathies are a group of neurodegenerative diseases including Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). These diseases are characterized by the aggregation and deposition of α-synuclein (α-syn) in Lewy bodies (LBs) in PD and DLB or as glial cytoplasmic inclusions in MSA. In...

Published: 9/15/2025 | Inventor(s): Gal Bitan

Keywords(s):

Category(s): Diagnostic Markers > Targets And Assays, Therapeutics > CNS and Neurology

1 2 3 4 5 6 7 8 9 10 ...